Similar articles

• Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

  Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE. Nicholls SJ, et al. JAMA. 2011 Nov 16;306(19):2099-109. doi: 10.1001/jama.2011.1649. JAMA. 2011. PMID: 22089718 Clinical Trial.
• Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.

  Nicholls SJ, Ruotolo G, Brewer HB, Kane JP, Wang MD, Krueger KA, Adelman SJ, Nissen SE, Rader DJ. Nicholls SJ, et al. J Am Coll Cardiol. 2015 Nov 17;66(20):2201-2210. doi: 10.1016/j.jacc.2015.09.013. J Am Coll Cardiol. 2015. PMID: 26564598 Clinical Trial.
• Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients.

  Nicholls SJ, Ruotolo G, Brewer HB, Wang MD, Liu L, Willey MB, Deeg MA, Krueger KA, Nissen SE. Nicholls SJ, et al. J Clin Lipidol. 2016 May-Jun;10(3):519-527.e4. doi: 10.1016/j.jacl.2015.11.014. Epub 2015 Dec 18. J Clin Lipidol. 2016. PMID: 27206939 Clinical Trial.
• Safety and Efficacy of Evacetrapib in Patients with Inadequately-controlled Hypercholesterolemia and High Cardiovascular Risk; A meta-analysis of Randomized Placebo-controlled Trials.

  Bahbah EI, Shehata MSA, Alnahrawi SI, Sayed A, Menshawey A, Fisal A, Morsi M, Gabr ME, Elbasit MSA. Bahbah EI, et al. Prostaglandins Leukot Essent Fatty Acids. 2021 May;168:102282. doi: 10.1016/j.plefa.2021.102282. Epub 2021 Apr 12. Prostaglandins Leukot Essent Fatty Acids. 2021. PMID: 33882411
• Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

  Tenenbaum A, Fisman EZ, Motro M, Adler Y. Tenenbaum A, et al. Adv Cardiol. 2008;45:127-153. doi: 10.1159/000115192. Adv Cardiol. 2008. PMID: 18230960 Review.